[go: up one dir, main page]

WO2014059091A3 - Procédés de modulation de la fonction mitochondriale par l'intermédiaire d'ifn2 - Google Patents

Procédés de modulation de la fonction mitochondriale par l'intermédiaire d'ifn2 Download PDF

Info

Publication number
WO2014059091A3
WO2014059091A3 PCT/US2013/064255 US2013064255W WO2014059091A3 WO 2014059091 A3 WO2014059091 A3 WO 2014059091A3 US 2013064255 W US2013064255 W US 2013064255W WO 2014059091 A3 WO2014059091 A3 WO 2014059091A3
Authority
WO
WIPO (PCT)
Prior art keywords
inf2
caax
mitochondrial function
activity
test agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/064255
Other languages
English (en)
Other versions
WO2014059091A2 (fr
Inventor
Henry N. HIGGS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of WO2014059091A2 publication Critical patent/WO2014059091A2/fr
Anticipated expiration legal-status Critical
Publication of WO2014059091A3 publication Critical patent/WO2014059091A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des dosages de criblage pour l'identification d'agents qui modulent la protéine contenant le domaine formine 2, FH2 et WH2 inversé, l'activité d'isoforme 2 (INF2-CAAX) ou la fonction mitochondriale à médiation par INF2-CAAX, et l'utilisation de tels agents dans l'amélioration d'une maladie associée au dysfonctionnement mitochondrial.
PCT/US2013/064255 2012-10-12 2013-10-10 Procédés de modulation de la fonction mitochondriale par l'intermédiaire d'ifn2 Ceased WO2014059091A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712951P 2012-10-12 2012-10-12
US61/712,951 2012-10-12

Publications (2)

Publication Number Publication Date
WO2014059091A2 WO2014059091A2 (fr) 2014-04-17
WO2014059091A3 true WO2014059091A3 (fr) 2015-08-20

Family

ID=50478061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/064255 Ceased WO2014059091A2 (fr) 2012-10-12 2013-10-10 Procédés de modulation de la fonction mitochondriale par l'intermédiaire d'ifn2

Country Status (1)

Country Link
WO (1) WO2014059091A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114700A2 (fr) * 2008-03-12 2009-09-17 The Trustees Of Columbia University In The City Of New York Modèle cellulaire de maladie neurodégénérative et procédés d’utilisation de celui-ci pour identifier des inhibiteurs de fusion mitochondriale

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114700A2 (fr) * 2008-03-12 2009-09-17 The Trustees Of Columbia University In The City Of New York Modèle cellulaire de maladie neurodégénérative et procédés d’utilisation de celui-ci pour identifier des inhibiteurs de fusion mitochondriale

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHHABRA ET AL.: "INF2 is an endoplasmic reticulum-associated formin protein", JOURNAL OF CELL SCIENCE, vol. 122, 14 April 2009 (2009-04-14), pages 14 3 0 - 1440 *
FRIEDMAN ET AL.: "ER Tubules Mark Sites of Mitochondrial Division", SCIENCE, vol. 334, 21 October 2011 (2011-10-21), pages 358 - 362 *
KOROBOVA ET AL.: "An Actin-Dependent Step in Mitochondrial Fission Mediated by the ER-Associated Formin INF2", SCIENCE, vol. 339, 25 January 2013 (2013-01-25), pages 464 - 467. *
PON, LIZA.: "Mitochondrial Fission: Rings around the Organelle", CURRENT BIOLOGY, vol. 23, no. Iss. 7, 1 April 2013 (2013-04-01), pages R279 - R281 *
RAMABHADRAN ET AL.: "Splice variant-specific cellular function of the formin INF2 in maintenance of Golgi architecture", MOLECULAR BIOLOGY OF THE CELL, vol. 22, no. 24, 15 December 2011 (2011-12-15), pages 4822 - 4833 *

Also Published As

Publication number Publication date
WO2014059091A2 (fr) 2014-04-17

Similar Documents

Publication Publication Date Title
Charfeddine et al. Financial development and environmental quality in UAE: Cointegration with structural breaks
PH12020551028A1 (en) Methods, kits and apparatus for expanding a population of cells
WO2015112534A3 (fr) Compositions et procédés pour moduler et réorienter des réponses immunitaires
PH12019502558A1 (en) Diagnostic assays for detecting, quantifying, and/or tracking microbes and other analytes
CA2951514C (fr) Methodes, compositions et dispositifs pour l'analyse rapide de marqueurs biologiques
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
WO2013052505A3 (fr) Procédés et dispositifs permettant d'évaluer le risque, chez une progéniture putative, de développer une maladie
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
WO2019105468A8 (fr) Méthodes d'utilisation du ligand cd137 comme biomarqueur pour le traitement avec un anticorps anti-cd137
EP2542581A4 (fr) Anticorps spécifique d'apolipoprotéine, et procédés d'utilisation correspondant
MX2016012079A (es) Dispositivo para deteccion de estados de enfermedad y aplicaciones del mismo.
EA201490328A1 (ru) Исследования для мониторинга нарушений свертываемости крови
WO2015095062A3 (fr) Procedes d'identification de modulateurs des recepteurs olfactifs
WO2016040824A3 (fr) Procédés d'identification de modulateurs de l'interaction sestrine-gator2 et utilisation de ceux-ci pour moduler le mtorc1
GB201014028D0 (en) In-situ reagent
WO2011159928A3 (fr) Anticorps agissant comme agonistes contre dr4
GB201206977D0 (en) An enzyme detection device
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
MX2020002395A (es) Metodos para evaluar conjugados de anticuerpos y farmacos.
MX2019010478A (es) Sistemas y métodos para la detección y cuantificación enzimáticas de a1c.
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2014059091A3 (fr) Procédés de modulation de la fonction mitochondriale par l'intermédiaire d'ifn2
WO2010000467A8 (fr) Asc en tant que marqueur du cancer du poumon
MX2017004630A (es) Metodos para llevar a cabo estudios de estimulo-respuesta con celulas madre pluripotentes inducidas derivadas de celulas perinatales o tejidos.
WO2007140308A3 (fr) Méthodes de criblage de modulateurs trpm4 de la sécrétion d'insuline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13844941

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13844941

Country of ref document: EP

Kind code of ref document: A2